Bioventus (BVS) reported Q4 non-GAAP earnings Tuesday of $0.15 per share, up from $0.07 a year earlier.
Three analysts surveyed by FactSet expected $0.08.
Revenue for the quarter ended Dec. 31 was $153.6 million, up from $135.4 million a year earlier.
Three analysts surveyed by FactSet expected $145.2 million.
Bioventus said it expects 2025 non-GAAP EPS of $0.64 to $0.68. Three analysts surveyed by FactSet expect $0.55.
Bioventus also said it expects 2025 net sales of $560 million to $570 million. Three analysts surveyed by FactSet expect $554.6 million.
The company's shares were up more than 26% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。